Novo Nordisk A/S (NYSE:NVO) Shares Sold by Sivia Capital Partners LLC

Sivia Capital Partners LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 11.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,949 shares of the company’s stock after selling 978 shares during the period. Sivia Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $684,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S in the second quarter valued at $25,000. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Abound Wealth Management grew its stake in Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S during the third quarter worth approximately $42,000. Finally, Carolina Wealth Advisors LLC purchased a new stake in Novo Nordisk A/S in the third quarter valued at approximately $48,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Price Performance

NYSE:NVO traded down $2.15 during trading hours on Monday, hitting $84.11. The company’s stock had a trading volume of 6,033,316 shares, compared to its average volume of 7,204,707. Novo Nordisk A/S has a 52-week low of $81.50 and a 52-week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The business’s 50-day moving average is $100.35 and its two-hundred day moving average is $119.04. The company has a market capitalization of $377.45 billion, a PE ratio of 27.22, a PEG ratio of 1.37 and a beta of 0.45.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.